White House Announces Drug Price Deal That Mostly Discounts Press Releases

Administration hails “historic savings on adjectives,” Americans may soon afford reading about medicine they still can’t buy.

The White House on Thursday unveiled a landmark agreement with drugmaker Regeneron that officials say will “dramatically lower the cost of pharmaceutical press conferences, talking points, and carefully staged patient anecdotes” across the United States.

“For too long, Americans have paid premium prices just to hear us say ‘bold step forward’ and ‘transformative partnership,’” said one senior official, announcing what the administration called the first-ever Drug Messaging Affordability Framework. “Today, we’re slashing the cost of those phrases by up to 40% over ten years.”

Historic Savings, If You Are a Chart

Under the deal, Regeneron has agreed to modestly reduce the price of select high-cost drugs in exchange for the federal government purchasing, in bulk, every future PowerPoint slide that references them. The slides will be stored in a new “Strategic Metaphor Reserve” under the Department of Health and Human Services.

An internal memo obtained by Political Chaos outlines the benefits: “Average American family will save up to 13% on exposure to optimistic bar graphs by 2035, assuming stable reality and no new diseases with better lobbyists.”

A Regeneron spokesperson praised the agreement as “a win-win for patients and shareholders who enjoy being described as caring deeply about patients.”

“We’re committed to access,” the spokesperson said. “Access to layered messaging, aspirational branding, and at least two smiling stock photo grandparents per slide.”

Administration economists say the plan will also introduce “generic synonyms” for expensive buzzwords. Under the deal, “innovative” will be replaced with the cheaper “kinda new,” while “life-changing” will be offered as “possibly helpful under certain billing codes.”

Emergency Task Force on Looking Like We Did Something

The announcement comes after months of negotiations, three leaked drafts, and the creation of the President’s Emergency Task Force on Optics, Value, and Making Senators Stop Yelling in Hearings (OVMSSYH), which concluded that “most voters just want to see a big number with arrows pointing down.”

To that end, the White House released a 67-page fact sheet showing projected savings in font size, podium height, and frequency of the word “historic.” Officials say these downstream efficiencies will “eventually, theoretically, in spirit” reach consumers.

“This is the most significant drug pricing action since the last press conference where we said something was the most significant drug pricing action,” declared the White House press secretary. “You simply cannot put a price on that—although Regeneron successfully did, and we negotiated 3% off.”

When asked if the deal would lower anyone’s actual prescription costs this year, a senior aide clarified: “We’re focused on long-term sustainability. By ‘long-term’ we mean ‘after this election cycle,’ and by ‘sustainability’ we mean ‘the sustainability of this talking point.’”

As part of the rollout, the administration promised to “keep fighting” for more aggressive reforms, including a pilot program where one lucky American will receive their medication at cost in exchange for appearing in 14 campaign ads and quietly signing an NDA.

At the end of the briefing, officials proudly displayed a large banner reading “Drug Prices: Going Down*” with a footnote explaining that the asterisk “reflects optimism, not a legally enforceable promise.” The banner reportedly cost more than a month’s supply of the average Regeneron therapy.

Reality Check

The real news: The White House is expected to announce a drug pricing agreement with pharmaceutical company Regeneron. Details are still emerging, but such deals typically aim to lower certain medication costs for patients or government programs. Our piece exaggerates the focus on messaging and optics for satire. For accurate information, refer to reputable news sources or official government releases as more specifics become public.

Image credit: Adriana Beckova — source. Show a visible credit link to Pexels on the site.